US biotech major Biogen (Nasdaq: BIIB) has entered into a global license and collaboration agreement with Ireland-incorporated biotech firm Alkermes (Nasdaq: ALKS) to develop and commercialize ALKS 8700, a novel, oral, monomethyl fumarate (MMF) small drug molecule in Phase III development for the treatment of relapsing forms of multiple sclerosis (MS).
Alkermes’ shares gained as much as 5.8% in pre-market trading, but levelled off, while Biogen was up 1%, both on light volume.
Alkermes’ compound has been seen as a potential threat to Biogen’s top-selling MS drug Tecfidera (dimethyl fumarate), which had sales of $845 million in the third quarter of this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze